Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies

Measuring the biological effect of presurgical metformin treatment in endometrial cancer

(2016) V N Sivalingam et al.   BRITISH JOURNAL OF CANCER

Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial

(2014) Akira Mitsuhashi et al.   CANCER

Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer

(2014) Ido Laskov et al.   GYNECOLOGIC ONCOLOGY

Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer

(2014) Tianbo Liu et al.   TUMOR BIOLOGY

Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer

(2014) Kevin M. Schuler et al.   Cancer Medicine

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma

(2013) Jutta Huvila et al.   GYNECOLOGIC ONCOLOGY

Neoadjuvant treatment of endometrial cancer using anastrozole: A randomised pilot study

(2013) Amudha Thangavelu et al.   GYNECOLOGIC ONCOLOGY

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

(2012) Douglas G. Altman et al.   PLOS MEDICINE

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute

Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

(2008) M. J. Ellis et al.   JNCI-Journal of the National Cancer Institute